Valuation: Evolutionary Genomics, Inc.

Market Cap 2.99M 2.68M 2.5M 2.27M 4.28M 286M 4.3M 30.03M 11.76M 148M 11.25M 11M 475M P/E 2021
-1.34x
P/E 2022 -2x
Enterprise Value 6.16M 5.52M 5.14M 4.66M 8.8M 589M 8.85M 61.79M 24.19M 304M 23.15M 22.63M 978M EV / Sales 2021
-
EV / Sales 2022 -
Free-Float
67.35%
Yield 2021 *
-
Yield 2022 -
1 day-27.14%
1 week+254,900.00%
Current month+254,900.00%
1 month+254,900.00%
3 months+254,900.00%
6 months+254,900.00%
Current year+254,900.00%
1 year 0
Extreme 0.0002
0.51
3 years 0
Extreme 0.0002
0.51
5 years 0
Extreme 0.0002
0.9
10 years 0
Extreme 0.0002
5.71
Manager TitleAgeSince
Chief Tech/Sci/R&D Officer 71 1999-12-31
Chief Executive Officer 70 2014-09-30
Director TitleAgeSince
Chairman 70 2014-09-30
Director/Board Member 76 1999-12-31
Director/Board Member 66 2009-12-31
Date Insider Type Main position Quantity % Market Cap. Importance
5/23/22 Exercice

Chief Executive Officer

185,715 2.8074%
5/23/22 Exercice

Founder

278,571 4.2111%
5/23/22 Exercice

Founder

55,714 0.8422%
Change 5-day change 1-year change 3-year change Capi.($)
-27.14%+254,900.00%+254,900.00%+13.33% 1.33K
+0.03%-5.67%+50.74%+76.76% 70.65B
-0.38%-12.51%+4.70%+54.09% 51.22B
-0.89%-1.28%+7.44%+36.04% 48.04B
+0.90%-1.46%+32.32%+32.69% 43.16B
+2.21%-6.61%+302.05%+701.45% 41.57B
-1.15%-3.11%+9.47%+98.83% 39.84B
+0.45%-1.20%+9.11%+43.54% 30.87B
-2.66%-11.49%+42.12%+4.38% 27.53B
-1.16%-1.84%-6.09%-11.99% 24.08B
Average -2.98%-3.08%+25,535.19%+104.91% 37.7B
Weighted average by Cap. -0.17%-3.47%+52.54%+120.99%

Financials

2021 2022
Net sales - -
Net income -2.79M -2.5M -2.33M -2.11M -3.99M -267M -4.01M -28.02M -10.97M -138M -10.5M -10.26M -444M -1.93M -1.73M -1.61M -1.46M -2.76M -185M -2.78M -19.41M -7.6M -95.45M -7.27M -7.11M -307M
Net Debt 3.53M 3.16M 2.95M 2.67M 5.04M 337M 5.07M 35.4M 13.86M 174M 13.26M 12.97M 560M 3.17M 2.83M 2.64M 2.4M 4.52M 303M 4.55M 31.76M 12.43M 156M 11.9M 11.63M 503M
Logo Evolutionary Genomics, Inc.
Evolutionary Genomics, Inc. is a genomics research and development company. The Company is focused on the identification and validation of genes that impact commercially valuable traits in crops for the agriculture industry. It has performed research on crops including rice, corn, soybeans, wheat, cotton, cowpeas, beans, tomatoes, and cassava. Its core technology is its patented Adapted Traits Platform (ATP), which is used to perform molecular evolution analysis to identify positively selected genes that may have an impact on traits of interest. Positively selected candidate genes must be further tested to validate their impact on the desired traits. The Company has applied its ATP in research projects, including identifying genes responsible for increases in yield in corn, increases in yield in rice, drought tolerance and sugar content in tomatoes and pest/disease resistance in soybeans, cassava, beans, tomatoes and cotton.
Employees
3
  1. Stock Market
  2. Stocks
  3. FNAM Stock